Smith & Nephew plc (SN.) — Investment Research Note

Executive summary

Smith+Nephew is a UK-listed portfolio medical technology company operating across three global business units — Orthopaedics (~40% of revenue), Sports Medicine & ENT (~31%), and Advanced Wound Management (~29%) — with 2025 revenue of $6,164m and $1,211m trading profit. The trajectory across the period covered has been one of gradual operational recovery: revenue growth accelerated from ~4.7% in 2022 to 5.3% in 2024/2025 while the trading margin rebuilt from 17.3% (2022) to 19.7% (2025) as the "12-Point Plan" delivered ~$280m of cumulative cost savings, culminating in the launch of the new "RISE" strategy targeting 6–7% revenue CAGR and 12–13% adjusted ROIC by 2028. The single most important point for valuation today is that after H1 2026's revenue guidance cut (from ~6% to 4%), management kept trading profit, FCF ($800m) and ROIC guidance intact — evidence that the productivity engine is real — but the shares now sit near the 52-week low, offering a mid-teens FCF yield and a discount to global medtech peers on largely self-help drivers.

Fair value estimate

Methodology: Blended forward P/E on EPSA, cross-checked with an EV/EBITDA multiple and an FCF yield anchor. All three approaches point to a similar range.

Key assumptions:

• 2025 EPSA of 102.0¢ (delivered); 2026E EPSA of ~113¢ using management's ~11% H1 growth extrapolated (H1 2026 delivered 47.7¢, up 11.0%)
• 2026 trading profit ~$1.3bn (management guidance held)
• 2026 free cash flow ~$800m (guidance held)
• Applied GBP/USD ~1.34 (current spot region)
• Peer forward P/E: Stryker ~28x, Zimmer Biomet ~15x, Medtronic ~17x; SN. trading at ~13x forward EPSA reflects deserved discount for Orthopaedics execution risk, but the discount has widened beyond fair
• Fair forward P/E band: 14–17x EPSA, giving a per-share range of ~1,180p to ~1,435p
• Cross-check on EV/EBITDA: 2025 adj EBITDA $1,607m × 12–14x = EV ~$19.3–22.5bn; less net debt $2.76bn = equity ~$16.5–19.7bn ≈ £12.3–14.7bn — supports the upper end
• FCF yield anchor: at ~£600m FCF (2026E) and 5% yield → ~£12bn market cap → ~1,430p

Fair value range: 1,150p – 1,400p per share (mid ~1,275p) Implied market cap range: £9,635m – £11,730m (mid ~£10,685m) vs current mcap £9,185m: upside ~5% to ~28%, midpoint ~+16%

Sector context

Sector: Health Care / Health Care Equipment & Services. Confirmed. SN. is a diversified medtech (orthopaedics + wound care + sports medicine) — this is a moderately-cyclical, high-quality defensive sub-sector. Growth (~5% underlying) and margins (~19.7% trading, ~13% IFRS operating) are below best-in-class peers like Stryker and Boston Scientific but roughly in line with Zimmer Biomet and Medtronic. Balance sheet leverage (1.7–1.8x EBITDA) is above the sector median (~1.0–1.5x). Listed peers: Stryker (SYK), Zimmer Biomet (ZBH), and — for the wound and sports medicine end — Boston Scientific (BSX) and CONMED (CNMD).

Investment thesis

• 12-Point Plan is delivering measurable margin expansion despite tough conditions. Trading margin has expanded ~240bps from 17.3% (2022) to 19.7% (2025) while absorbing ~1,000bps of macro headwinds (China VBP, FX, inflation). Management now targets ≥20% in 2025 achieved and a further step-up under RISE, with $325–375m of cumulative savings by 2027 2026-03-02 final results; 2026-08-04 H1.
• Sports Medicine & ENT and Advanced Wound Management (~60% of Group) are structurally strong compounders. Sports Medicine JR grew 10.3% underlying in 2025 (11.8% in Q2 2026 excl. China), with proven acquisitions (REGENETEN, CARTIHEAL, Tendon Seam) building a differentiated shoulder/knee repair leadership; Wound delivered 5.6% underlying growth in 2025 with double-digit NPWT growth 2026-03-02 final results; 2026-08-04 H1.
• Cash generation and shareholder returns have inflected sharply. FCF grew 15-fold from $56m (2022) to $840m (2025), enabling both a $500m 2025 buyback and a fresh $500m 2026 buyback (in progress; $216m settled by 3 Aug 2026), against an already progressive dividend. Together these represent >6% of market cap being returned 2026-05-06 Q1; 2026-08-04 H1.

Key risks

• US Orthopaedics execution remains fragile. US Knee Implants declined -7.2% in Q2 2026 and US Hip Implants -1.5%, driving the full-year revenue guidance cut from ~6% to ~4%. Recovery relies on the H2 2026 launch of cementless LANDMARK — a single-product-launch dependency 2026-08-04 H1 report.
• China VBP and reimbursement resets are recurring headwinds. Sports Medicine JR VBP started 2024, ENT VBP delayed to H2 2026, and US skin substitute reimbursement reset is now expected at the upper end of the $20–40m 2026 headwind. Government pricing risk in medtech will remain a chronic feature 2026-08-04 H1; 2025-08-05 H1.
• Litigation & product-line rationalisation drag reported earnings. Metal-on-metal hip claims recur every reporting cycle, and 2025 included a $159m E&O provision on discontinued Orthopaedics SKUs. The gap between IFRS EPS (72.1¢) and adjusted EPSA (102.0¢) in 2025 is ~30% — a persistent quality-of-earnings watch 2026-03-02 final results.

Operating leverage

Smith+Nephew has moderate operating leverage. The cost base is a mix of high-fixed (manufacturing plant, sales-force headcount, R&D at ~5% of sales, corporate ~$400m) and variable (COGS ~29% of revenue). Trading gross margin was 70.9% in 2025 (H1 2026: 71.1%) — genuinely software-like at the gross line but eroded by SG&A running at ~52% of revenue. The revealed incremental margin over 2023–2025 was strong: revenue grew ~$615m while trading profit grew ~$241m, implying ~39% incremental margin — well above the ~19.7% average trading margin. A 10–20% revenue upside surprise over current expectations would likely deliver ~30–50% incremental trading profit uplift (i.e. add ~$400–800m to trading profit vs a $1.3bn 2026E base). Business unit disclosure confirms leverage: Sports Medicine trading margin expanded 160bps to 24.7% on 7.7% underlying growth in H1 2026; Ortho margin expanded 30bps to 13.0% even with declining revenue, evidencing genuine productivity gains (network optimisation, factory closures in France, China, Germany completed; new Malaysia plant on stream). However, this is a capital-heavy business (2025 capex $433m, DSI still elevated at ~120 days) with a large instrument-set installed base — not a capital-light scale-economics story 2026-08-04 H1; 2026-03-02 final results.

Value-trap signals

• Frequent "trading" adjustments recur. Restructuring costs of $220m (2023), $123m (2024), $47m (2025) and legal/other of $58–162m are recurring — the reported EPS trails EPSA persistently.
• US Orthopaedics has now missed expectations 3+ years running, with the newly launched LANDMARK Knee System being the third attempted turnaround.
• Full-year 2026 revenue guidance cut in August 2026 (~6% → ~4%) is the second downward revision in the RISE-strategy period.

Not a full value trap: the diversified franchises (60% of revenue) are growing well, the balance sheet is investment grade, dividends are progressive not cut, and management is actively returning capital.

Earnings vs. expectations

Guidance track record over the covered filings:

• 2023: guided ~5–6% revenue and ~17.5% margin (Feb 2023); delivered 7.2% underlying revenue growth ($5,549m) and 17.5% margin — modest beat on revenue, in line on margin.
• 2024: guided 5–6% revenue and ≥18% margin; delivered 5.3% underlying and 18.1% margin — in line.
• 2025: guided ~5% revenue and 19.0–20.0% margin; delivered 5.3% and 19.7% margin — in line/slight beat.
• 2026: initially guided ~6% revenue and around $1.3bn trading profit (Feb/May 2026); in Aug 2026 revenue cut to ~4% while trading profit reaffirmed — miss on top line, beat/hold on profit.

Pattern: consistently delivers on trading profit / margin commitments, but 2026 revenue miss shows the top line is more fragile than management projected, largely due to US Orthopaedics execution. Overall: more meets/beats than misses, but the 2026 revenue miss is material.

Conviction

Conviction: 4 (high). The financial disclosure is deep and consistent, multi-year restructuring is now visible in the numbers, the H1 2026 half-year statements are recent, and three cross-checked valuation approaches (forward P/E, EV/EBITDA, FCF yield) all point to a similar 1,150–1,400p range. Anchors: (1) 2025 EPSA of 102.0¢ is a delivered, audited figure; (2) H1 2026 EPSA growth of 11% supports the near-term forecast; (3) $800m FCF guidance for 2026 has been reaffirmed. Limiting factors: (1) heavy use of non-IFRS "trading" adjustments (~30% gap between EPS and EPSA in 2025) creates some interpretive risk around underlying earnings power; (2) US Orthopaedics execution has repeatedly disappointed, adding uncertainty to the 2028 RISE targets.

Driver scoring

• ai_beneficiary (20): No meaningful AI-receiver exposure. Mentions of AI in filings (TESSA Spatial Surgery System, CORIOGRAPH planning, digital twin in supply chain) are internal-use or product marketing — SN. spends on AI in operations, but does not sell into the AI value chain and has no revenue line whose addressable market expands materially with AI adoption.
• operating_leverage (48): Moderate. Trading gross margin ~71% is software-like but SG&A base absorbs most of it. Realised incremental margins of ~39% (2023–2025) are above segment average, but this is a capital-heavy, instrument-set-intensive business rather than a spare-capacity operator.
• earnings_surprise_trend (55): More beats than misses on trading profit and margin over 2023–2025; H1 2026 miss on revenue puts recent trend closer to "in line" than "beat".
• cyclicality (28): Medical devices are largely defensive (elective procedures deferred but not eliminated); some sensitivity to hospital capex cycles and Chinese VBP.
• moat (58): Strong in Sports Medicine biologics (REGENETEN, CARTIHEAL) and Wound (SANTYL enzymatic debrider franchise, extensive evidence base), moderate in Orthopaedics (share loser in US knees, but strong hip/robotics platform via CORI). Not dominant like Stryker/Intuitive, but genuinely differentiated in chosen segments.
• leverage (45): 1.7–1.8x adj EBITDA; investment grade; $500m buyback funded without stressing balance sheet. Meaningful but not concerning.
• earnings_quality (55): Cash conversion recovered strongly to 102% in 2025; but recurring restructuring, legal charges and portfolio rationalisation E&O provisions mean IFRS EPS trails EPSA persistently. Trading definitions are transparent but heavily used.
• management_quality (58): CEO Deepak Nath (appointed 2022) has stabilised the ship and delivered 12-Point Plan targets. RISE strategy launched Dec 2025 with credible 2028 targets. Capital allocation improved (dividend policy formalised, first-ever buybacks, sensible M&A). Not yet demonstrably exceptional.
• growth_momentum (58): Mid-single-digit underlying growth, decelerating slightly in H1 2026 (2.3%) but expected to reaccelerate in H2. Multi-year trajectory is stable/mid-single-digit — not accelerating.

Overall score

340 / 1000. The stock is a fair-priced, moderate-quality defensive medtech compounder trading at a reasonable ~13x forward EPSA with a >5% shareholder yield, but it is a poor fit for the specific AI-receiver / operating-leverage / long-tail-upside strategy this investor is building. The AI exposure is minimal (spending on AI internally, not selling into it), operating leverage is moderate not exceptional, and the upside case does not deliver "multiples of profit" from a revenue surprise. Valuation is fair-to-slightly-cheap (mid-teens upside to fair value) with acceptable downside protection, but a generalist investor looking for defensive medtech at a discount would rate this more highly than the AI-focused framework specified.